MX2013003179A - Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral. - Google Patents

Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral.

Info

Publication number
MX2013003179A
MX2013003179A MX2013003179A MX2013003179A MX2013003179A MX 2013003179 A MX2013003179 A MX 2013003179A MX 2013003179 A MX2013003179 A MX 2013003179A MX 2013003179 A MX2013003179 A MX 2013003179A MX 2013003179 A MX2013003179 A MX 2013003179A
Authority
MX
Mexico
Prior art keywords
nucleoside analogs
fluoro substituted
antiviral treatment
substituted carba
nucleoside
Prior art date
Application number
MX2013003179A
Other languages
English (en)
Spanish (es)
Inventor
Aesop Cho
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013003179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013003179A publication Critical patent/MX2013003179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013003179A 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral. MX2013003179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PCT/US2011/029441 WO2012039791A1 (en) 2010-09-20 2011-03-22 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
MX2013003179A true MX2013003179A (es) 2013-04-24

Family

ID=47748238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003179A MX2013003179A (es) 2010-09-20 2011-03-22 Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral.

Country Status (21)

Country Link
EP (1) EP2619206A1 (ko)
JP (4) JP2013538230A (ko)
KR (1) KR101879887B1 (ko)
CN (1) CN103108876A (ko)
AP (1) AP3699A (ko)
AU (1) AU2011306066B2 (ko)
BR (1) BR112013008017A2 (ko)
CA (1) CA2807496C (ko)
CL (1) CL2013000727A1 (ko)
CO (1) CO6680669A2 (ko)
CR (1) CR20130172A (ko)
EA (1) EA026523B1 (ko)
EC (1) ECSP13012560A (ko)
IL (1) IL225221A0 (ko)
MA (1) MA34593B1 (ko)
MX (1) MX2013003179A (ko)
NZ (1) NZ608070A (ko)
PE (3) PE20171624A1 (ko)
SG (1) SG188223A1 (ko)
WO (1) WO2012039791A1 (ko)
ZA (1) ZA201301042B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038946T2 (hu) 2008-04-23 2018-12-28 Gilead Sciences Inc 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
AU2010295392B2 (en) 2009-09-21 2015-10-22 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
ES2659216T5 (es) 2011-09-16 2021-06-09 Gilead Pharmasset Llc Métodos para el tratamiento del VHC
PE20151778A1 (es) 2013-01-31 2015-12-16 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
CN104230985B (zh) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
JP6742403B2 (ja) 2015-09-16 2020-08-19 ギリアード サイエンシーズ， インコーポレイテッド アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
AR111490A1 (es) 2017-05-01 2019-07-17 Gilead Sciences Inc Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)
EP3651734A1 (en) 2017-07-11 2020-05-20 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
BR112020010581A2 (pt) 2017-12-07 2020-11-10 Emory University composição farmacêutica, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e de tratamento ou prevenção de coronavírus humano, sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus chikungunya e infecção por infecção de ross river, vírus orthomyxoviridae ou vírus paramyxoviridae ou vírus rsv, ou infecção pelo vírus influenza a e vírus influenza b ou vírus filoviridae ou vírus ebola.
TW202313067A (zh) 2020-01-27 2023-04-01 美商基利科學股份有限公司 治療sars cov-2感染之方法
EP4118085A2 (en) 2020-03-12 2023-01-18 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
AU2021296841A1 (en) 2020-06-24 2023-02-16 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
DK4204421T3 (da) 2020-08-27 2024-05-27 Gilead Sciences Inc Forbindelser og fremgangsmåder til behandling af virale infektioner
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023207942A1 (zh) * 2022-04-25 2023-11-02 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
NZ526703A (en) 2001-01-22 2004-12-24 Merck & Co Inc Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
CN100503628C (zh) * 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
EP3109244B1 (en) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006065335A2 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
HUE038946T2 (hu) * 2008-04-23 2018-12-28 Gilead Sciences Inc 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
UA112140C2 (uk) * 2009-02-10 2016-07-25 Гіліад Сайєнсіз, Інк. Нуклеозидні похідіні (варіанти), фармацевтична композиція на їх основі, спосіб лікування вірусної інфекції та застосування сполуки для виробництва лікарського засобу
RS55699B1 (sr) * 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje

Also Published As

Publication number Publication date
EP2619206A1 (en) 2013-07-31
AU2011306066A1 (en) 2013-02-28
AP3699A (en) 2016-05-31
JP2019014726A (ja) 2019-01-31
PE20230684A1 (es) 2023-04-21
CA2807496C (en) 2019-01-22
CR20130172A (es) 2013-05-29
BR112013008017A2 (pt) 2016-06-14
PE20131165A1 (es) 2013-10-14
MA34593B1 (fr) 2013-10-02
PE20171624A1 (es) 2017-11-02
JP6475280B2 (ja) 2019-02-27
ZA201301042B (en) 2014-07-30
CL2013000727A1 (es) 2013-08-23
WO2012039791A1 (en) 2012-03-29
KR20130110168A (ko) 2013-10-08
NZ608070A (en) 2015-11-27
CO6680669A2 (es) 2013-05-31
EA201390141A1 (ru) 2013-09-30
AP2013006767A0 (en) 2013-03-31
JP2016074732A (ja) 2016-05-12
JP2017119726A (ja) 2017-07-06
IL225221A0 (en) 2013-06-27
JP2013538230A (ja) 2013-10-10
SG188223A1 (en) 2013-04-30
CA2807496A1 (en) 2012-03-29
ECSP13012560A (es) 2013-06-28
KR101879887B1 (ko) 2018-07-18
EA026523B1 (ru) 2017-04-28
AU2011306066B2 (en) 2015-01-29
CN103108876A (zh) 2013-05-15

Similar Documents

Publication Publication Date Title
MX2013003179A (es) Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral.
AU2018204449B2 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EA201691623A1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
WO2012142523A3 (en) 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
MX2013000656A (es) Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros.
PH12014502771A1 (en) Nucleoside phosphoramidate prodrugs
CA2807584C (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
MX345562B (es) Analogos de carba-nucleosido para tratamiento antiviral.
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
TW200745151A (en) Antiviral nucleosides
NZ593647A (en) Synthesis of purine nucleosides
MD4403C1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
NZ706985A (en) 2’-chloro nucleoside analogs for hcv infection
NZ617066A (en) Nucleoside analogs
UA111163C2 (uk) Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
NZ631182A (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
NZ629428A (en) Substituted nucleosides, nucleotides and analogs thereof
MX2010013768A (es) Fosfatos ciclicos de nucleosidos.
NZ630890A (en) Microrna compounds and methods for modulating mir-122
UA102687C2 (ru) 1'-замещенные карбануклеозидные аналоги для противовирусной терапии
MX2012002958A (es) Compuestos antivirales heterociclicos.
MY183638A (en) Nucleoside phosphoramidate prodrugs
MY183716A (en) Nucleoside phosphoramidate prodrugs
MX2013001273A (es) Compuestos heterociclicos antivirales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal